Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
200 participants
Oct 19, 2023
OBSERVATIONAL
Conditions
Summary
Surgery plays significant role in treatment of neurogenic tumors, both for benign ganglioneuroma and for high risk neuroblastoma. The world literature has accumulated large experience in laparoscopic surgery for abdominal neuroblastoma. The presence of IDRF (image-defined risk factors) and tumor size (\>4-7 cm) are considered as common contraindications for minimally invasive surgery in neuroblastoma. However, the recent studies have shown that presence of IDRF is not an absolute contraindication for laparoscopic surgery. This open-label, nonrandomized, observational, phase III evaluates role and weight of different surgical risk factors (including IDRF, tumor size, tumor localization, tumor volume/patient height ratio, previous open surgical procedures, previous chemotherapy etc.) in the laparoscopic neuroblastoma resections. The aim of this study is to create novel risk factors scoring system for laparoscopic surgery in abdominal neuroblastoma.
Eligibility
Inclusion Criteria16
- Patients with neurogenic tumors meeting the criteria of groups I-III:
- Group I
- low or moderate risk group according to pilot difficulty scoring system (less than 5 points, see supplementary material);
- no IDRF;
- Group II:
- low or moderate risk group according to pilot difficulty scoring system (less than 5 points);
- patients with any number of IDRFs and without central tumor location and/or tumor extension across the midline and/or tumor volume (cm3)/patient height (m) ratio = 28 or more.
- Group III:
- and more IDRF + central tumor location and/or tumor extension across the midline;
- and more IDRF + tumor volume (cm3)/patient height (m) ratio = 28 or more;
- and more IDRF + 2 and more other risk factors according to pilot difficulty scoring system;
- IDRF + tumor extension across the midline + tumor volume (cm3)/patient height (m) ratio = 28 or more.
- Age from 0 to 18 years.
- Preoperative imaging (abdominal contrast-enhanced computed tomography (CT), performed no later than 14 days before the planned surgery).
- Indications for surgery based on the decision of multidisciplinary experts board in centers- participants.
- Written voluntary informed consent of the patient and / or his legal representative.
Exclusion Criteria5
- and more IDRF + central tumor location and/or tumor extension across the midline and/or tumor volume (cm3)/patient height (m) ratio = 28 or more.
- Severe concomitant pathology, increasing anesthesiologic and surgical risks, via the desicion of the research physician or conclusion by multidisciplinary team in centers- participants.
- Tumor volume does not technically allow to provide minimally-invasive surgery, based on the conclusion of multidisciplinary experts board team in centers- participants.
- Therapy strategy: observation
- \-
Interventions
Intraoperative- duration from the beginning of the skin incision to skin suture (min)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06296732